Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Nov 02, 2021 4:53pm
130 Views
Post# 34079326

RE:RE:RE:RE:FYI

RE:RE:RE:RE:FYISort of depends whether or not she got an offer she couldn't refuse. She was rather junior at Vertex so likely wasn't expensive. Could easily be picked off if someone wanted her - especially for a Boston company where she'd finally have an office. I notice on linked in she's "liking" posts for a small public company called Cybin based in Boston. Could mean nothing. But her Linkedin isnt' updated for anything yet. 

SPCEO1 wrote: More negative if she left of her own accord as that may indicate something negative regarding cancer's prospects. If she was asked to leave, that may indicate they do not think she is the person they need as they launch into something much bigger. 

qwerty22 wrote:

Either way seems negative.

 

SPCEO1 wrote: I have been told by a none company source that her departure is official. I don't know if she left or was asked to leave.
 

 

SPCEO1 wrote: I suspect this means something, but it could just be some sort of screw up, but I have been told that Leah's phone number now gives a message that her number has been disconnected.

 

 

 




<< Previous
Bullboard Posts
Next >>